The key catalyst is FDA feedback on the new brilaroxazine formulation expected in Q4 2026, which will determine the path for the RECOVER-2 trial and NDA submission. The company's cash runway of $17.5 million is limited, and patient enrollment is explicitly contingent on additional financing, making the capital raise timeline critical to watch alongside the FDA feedback.
Drug in focus
RVPH drug pipeline →brilaroxazine
◆ Mixed Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- If approved, brilaroxazine is at least 3-5 years from potential commercialization. RECOVER-2 enrollment is expected to begin in 1H 2027 (subject to financing), followed by a multi-year trial, NDA submission, and FDA review.
- Next catalyst
- None dated
What to watchThe immediate catalyst is FDA feedback on the new brilaroxazine formulation, expected in Q4 2026 (any day now). Positive feedback would clear a path for RECOVER-2 and NDA; negative feedback or a request for more data would likely pressure the stock further. Separately, the company needs to raise additional capital before RECOVER-2 enrollment can begin in 1H 2027, and its OTCQB listing limits financing options.
Price Chart
How similar events traded
Executive Summary
Reviva reported Q3 2026 net loss of $2.3 million ($0.17 per share), narrower than the $4.0 million loss in Q3 2025 and slightly better than the consensus estimate of a $0.18 loss. The company highlighted FDA feedback expected in Q4 2026 on a new brilaroxazine formulation for the RECOVER-2 Phase 3 trial, with patient enrollment contingent on additional financing, and a patent application granted priority examination potentially extending protection through 2046.
Key Financial Metrics
Key Facts
- Net loss of $2.3 million ($0.17 per share) for Q3 2026 vs. $4.0 million ($1.09 per share) in Q3 2025
- Cash and cash equivalents $17.5 million as of September 30, 2026, up from $14.4 million at year-end 2025
- FDA feedback on new brilaroxazine formulation expected in Q4 2026
- Bioequivalence study for new formulation expected to start Q1 2027
- RECOVER-2 Phase 3 patient enrollment expected to begin in 1H 2027, subject to additional financing
- Composition of matter patent application for new formulation granted priority examination (Track 1), potential patent extension through 2046
- Company anticipates filing for Nasdaq relisting in 1H 2027
- Shares outstanding increased to 13.1 million from 5.9 million at year-end 2025, reflecting reverse stock split and capital raises
Financial Impact
Net loss improved by $1.7 million year-over-year; cash position increased by $3.0 million since year-end 2025
Risk Factors
- Patient enrollment in RECOVER-2 is subject to additional financing, creating execution risk
- Stock trades on OTCQB with limited liquidity; Nasdaq relisting application not until 1H 2027
- Pre-revenue biotech with no approved products; depends entirely on clinical and regulatory milestones
- New formulation introduces regulatory uncertainty pending FDA feedback
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402358 |
Track record
12 reports on RVPH
2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +22.98% at T+20 after the Jul 10, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 3/10 No price data
- Nov 12, 20264d ago Press Release Neutral 4/10 Viewing Entry $0.3400 Now $0.3504 +3.07% settles Feb 11
- Nov 9, 20267d ago DEF 14A Neutral 4/10 Entry $0.3521 Now $0.3504 −0.47% settles Feb 8
- Aug 12, 202613w ago Press Release Neutral 4/10 Entry $0.3521 to $0.3521 Now $0.3504 −0.47% · 0.00% +5.48% vs SPY
- Jul 10, 202618w ago 25-NSE Bearish 7/10 Entry $0.6200 to $0.5000 Now $0.3504 +43.48% ▲ +19.35% +22.24% vs SPY
- May 13, 202626w ago Press Release Bearish 7/10 Entry $0.3900 to $0.4303 Now $0.3504 +10.14% ▼ −10.33% −6.74% vs SPY
- May 13, 202626w ago 8-K Bearish 8/10 Entry $0.3521 to $0.4775 Now $0.3504 +0.47% ▼ −35.62% −31.19% vs SPY
- Apr 15, 202630w ago 8-K Neutral 5/10 Entry $0.8900 to $0.5731 Now $0.3504 −60.62% ▼ −35.61% −43.74% vs SPY
- Mar 30, 202633w ago Press Release Mixed 6/10 Entry $0.6600 to $0.6000 Now $0.3504 −46.90% ▼ −9.09% −25.58% vs SPY
- Mar 18, 202634w ago Press Release Bearish 6/10 Entry $0.8300 to $0.7000 Now $0.3504 +57.78% ▲ +15.66% +30.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers